Citywide Infectious Diseases Conference (March 6, 2024)

Needs Statement

Infectious disease physicians, fellows, residents, medical students, pharmacists, and other healthcare professionals and trainees need to receive regular updates on guidelines regarding the diagnosis and treatment of infectious diseases and recent advances in the field. The series will examine a wide range of topics, such as hospital-acquired infections, multi-drug antimicrobial resistance, viral respiratory infections, and opportunistic infections in patients with HIV/AIDS and in transplant recipients. The series also aims to expand the clinical knowledge of learners, promote guideline-based medical practice, enhance the quality of patient care, and improve outcomes.

Educational Objectives

At the conclusion of the sessions, the participants should be able to:

• Identify and implement current clinical best practices for the diagnosis and treatment of hospital-acquired infections.
• Distinguish evidence-based strategies for diagnosing and treating COVID-19 and other viral respiratory infections.
• Recognize the various clinical manifestations of common opportunistic infections in patients with HIV/AIDS and in transplant recipients.
• Develop strategies to recognize and treat multidrug-resistant infections.

Target Audience

Accreditation/Credit Designation

Baylor College of Medicine is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Baylor College of Medicine designates this live activity for a maximum of 1.0 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Disclosure Policy

Baylor College of Medicine (BCM) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education (CME) for physicians. BCM is committed to sponsoring CE activities that are scientifically based, accurate, current, and objectively presented.

In accordance with the ACCME Standards for Commercial Support, BCM has implemented a mechanism requiring everyone in a position to control the content of an educational activity (i.e., directors, planning committee members, faculty) to disclose any relevant financial relationships with commercial interests (drug/device companies) and manage/resolve any conflicts of interest prior to the activity. Individuals must disclose to participants the existence or non-existence of financial relationships at the time of the activity or within 24 months prior.

In addition, BCM has requested activity faculty/presenters to disclose to participants any unlabeled use or investigational use of pharmaceutical/device products; to use scientific or generic names (not trade names) in referring to products; and, if necessary to use a trade name, to use the names of similar products or those within a class. Faculty/presenters have also been requested to adhere to the ACCME's validation of clinical content statements.

BCM does not view the existence of financial relationships with commercial interests as implying bias or decreasing the value of a presentation. It is up to participants to determine whether the relationships influence the activity faculty with regard to exposition or conclusions. If at any time during this activity you feel that there has been commercial/promotional bias, notify the Activity Director or Activity Coordinator. Please answer the questions about balance and objectivity in the activity evaluation candidly.

All of the relevant financial relationships listed for these individuals have been mitigated.